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GRAPHICAL ABSTRACT 
 
HIGHLIGHTS 
 Synthesis of methoxy and 4-thio derivatives of quercetin and luteolin is reported. 
 The majority of these compounds exhibited potential antiangiogenic activity. 
 The active compounds displayed high binding affinities with VEGF and VEGFR2. 
 Structure-activity relationships are defined. 
 Antiproliferative activity and membrane perturbation effects are presented. 
ABSTRACT: The formation of new blood vessels from the pre-existing vasculature 
(angiogenesis) is a crucial stage in cancer progression and, indeed, angiogenesis inhibitors are 
now used as anticancer agents, clinically. Here we have explored the potential of flavonoid 
derivatives as antiangiogenic agents. Specifically, we have synthesised methoxy and 4-thio 
derivatives of the natural flavones quercetin and luteolin, two of which (4-thio quercetin and 4-
thio luteolin) had never been previously reported. Seven of these compounds showed significant 
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(P<0.05) antiangiogenic activity in an in vitro scratch assay. Their activity ranged from an 86% 
inhibition of the vascular endothelium growth factor (VEGF)-stimulated migration (observed for 
methoxyquercetin at 10 µM and for luteolin at 1 µM) to a 36% inhibition (for thiomethoxy 
quercetin at 10 µM). Western blotting studies showed that most (4 out of 7) compounds 
inhibited phosphorylation of the VEGF receptor-2 (VEGFR2), suggesting that the 
antiangiogenic activity was due to an interference with the VEGF/VEGFR2 pathway. Molecular 
modelling studies looking at the affinity of our compounds towards VEGFR and/or VEGF 
confirmed this hypothesis, and indeed the compound with the highest antiangiogenic activity 
(methoxyquercetin) showed the highest affinity towards VEGFR and VEGF. As reports from 
others have suggested that structurally similar compounds can elicit biological responses via a 
non-specific, promiscuous membrane perturbation, potential interactions of the active 
compounds with a model lipid bilayer were assessed via DSC. Luteolin and its derivatives did 
not perturb the model membrane even at concentrations 10 times higher than the biologically 
active concentration and only subtle interactions were observed for quercetin and its derivatives. 
Finally, cytotoxicity assessment of these flavonoid derivatives against MCF-7 breast cancer cells 
demonstrated also a direct anticancer activity albeit at generally higher concentrations than those 
required for an antiangiogenic effect (10 fold higher for the methoxy analogues). Taken together 
these results show promise for flavonoid derivatives as antiangiogenic agents.  
KEYWORDS: Angiogenesis, flavones, quercetin, luteolin, antiangiogenic therapy 
1 INTRODUCTION 
Angiogenesis is a physiological process involving the formation of new blood vessels from pre-
existing blood vessels. It is a complex process characterized by the proliferation, migration, 
sprouting and elongation of endothelial cells [1], and plays an important role during cell 
reproduction and organ development, as well as in wound healing processes. Under pathological 
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conditions, angiogenesis is poorly regulated and contributes to the pathogenesis of various 
diseases such as rheumatoid arthritis, inflammation, psoriasis, degenerative eye conditions and, 
of particular relevance to our study, cancer [2]. Sustained angiogenesis is one of the central 
hallmarks of cancer [3,4] and has been validated as a key target for cancer therapy [5], as 
evidenced by several antiangiogenic agents having entered clinical practice in the last decade 
(for example, bevacizumab (Avastin
® 
for several metastatic cancers) and  sunitinib 
maleate (SU11248, Sutent
®
 for renal cell carcinoma and gastrointestinal stromal tumour)). 
Flavonoids are polyphenolic compounds that have attracted ongoing and recent interest due to 
their potential anticancer properties. They are very well known for their antiproliferative 
activities against various cell lines [6] with some flavonoids such as flavopiridol [7–9], silibinin 
(also known as silybin) [10], quercetin [11] and its derivative QC12 [12] having progressed to 
various stages of clinical trials. Interestingly, recent studies have highlighted that two common 
dietary flavonoids (quercetin and luteolin) inhibit angiogenesis in vitro and in vivo [13,14] at 
concentrations 10-40 µM. Also, other structurally similar flavones have been reported to possess 
antiangiogenic properties. In order to develop and optimise the flavone scaffolds into a 
pharmaceutical agent, a better understanding of the structure-activity relationships (SARs) is 
crucial. Hence, in this study, the antiangiogenic properties of a panel of small molecules, 
comprised of quercetin and luteolin, as well as their rationally designed and synthesised 
derivatives, are probed to allow a better understanding of the structure activity relationships of 
flavonoids as antiangiogenic agents. 
Many antiangiogenic agents exhibit their action by interfering with the vascular endothelial 
growth factor (VEGF) and the VEGF receptor-2 (VEGFR2) [15]. Therefore, the compounds 
reported in our study were evaluated for their potential to inhibit the VEGF-stimulated effects in 
an in vitro model comprised of endothelial cells. The molecular mechanism of action of these 
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derivatives was investigated using Western blotting and additionally in silico studies were 
conducted to probe the interactions of this panel of molecules with VEGFR2 and VEGF. 
Additionally, we probed the interactions of these synthesised compounds with a model lipid 
bilayer in order to determine the possible contribution of a membrane perturbation effect 
towards the observed biological activity. Finally, as flavonoid derivatives are known to display 
direct anticancer activity against tumour cells, cytotoxicity studies against a breast cancer cell 
line (MCF-7) and a chemotherapy resistant sub-strain (MCF-7/DX) were also carried out. This 
cytotoxicity assessment was carried out to investigate how variations in the chemical structure 
of the flavonoid derivatives affected their activity, but also to establish the concentrations 
required to elicit direct anticancer activity compared to those required for antiangiogenic effects. 
Indeed, a widely reported problem associated with antiangiogenic drugs that target endothelial 
proliferation is their inhibition of the proliferation of other cell types, which leads to undesirable 
cell toxicity; molecules with high selectivity towards VEGF/VEGFR2 with low cytotoxicity are 
considered to be ideal candidates for antiangiogenic therapy as well as for combination therapy 
[16]. 
2 RESULTS AND DISCUSSION 
This paper reports the synthesis of methoxy and 4-thio derivatives of quercetin and luteolin, 
which includes two new derivatives (4 and 12) and explores how subtle variations in the 
chemical structure of flavonoids affect their biological activity, particularly in relation to their 
antiangiogenic activity. 
2.1 Synthesis 
In order to gain a better understanding of SARs, a rational panel of compounds (2-4 and 9-12) 
comprised of flavonoids with differing numbers of hydroxyl groups (quercetin versus luteolin), 
different lipophilicities (hydroxyl versus methylated derivatives), and different key functional 
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groups (4-C=O versus 4-C=S) (Figure-1) was synthesised in good yields (ranging from 20% to 
30% overall yield). The derivatives of quercetin (2-4) and luteolin (9-12) were prepared using 
the general synthetic approaches outlined in Scheme-1 and 2 respectively.  
Synthesis of quercetin derivatives: The polymethylated derivative of quercetin, namely 
methoxyquercetin (2) was obtained by the methylation of quercetin (1) using dimethyl sulfate in 
the presence of 15% KOH, in 60% yield. The compound methoxyquercetin (2) was treated with 
Lawesson’s reagent in anhydrous toluene to obtain the 4-thio derivative, thiomethoxyquercetin 
(3) in 65% yield. The thiomethoxyquercetin (3) was demethylated using BBr3 in anhydrous 
dichloromethane at 40 
o
C for 18 h to afford thioquercetin (4) in 55% yield (Scheme-1). 
Synthesis of luteolin derivatives: The first step in the synthesis of luteolin (10) and its 
derivatives was esterification of 2-hydroxy-4,6-dimethoxyacetophenone (5) with 3,4-dimethoxy 
benzoyl chloride (6) in pyridine and this was achieved in 60% yield. The obtained ester (7) was 
converted to a 1,3-diketone (8) via a Baker-Venkataramann rearrangement in the presence of 
KOH in pyridine in approximately 75% yield. This 1,3-diketone (8) underwent cyclo-
dehydration in the presence of an acid to give the methoxyluteolin (9) in 70% yield. The 
hydroxy flavone, luteolin (10), was obtained by demethylation of methoxyluteolin using BBr3 in 
anhydrous dichloromethane at 40 
o
C for 18 h in 59% yield. The 4-thiomethoxy derivative of 
luteolin (11) was obtained in 61% yield by treating the methoxyluteolin (9) with Lawesson’s 
reagent. Thioluteolin (12) was successfully synthesised by the demethylation of 
thiomethoxyluteolin (11) using BBr3 in anhydrous dichloromethane at 40 
o
C for 18 h in 55% 
yield (Scheme-2). The identities of these synthesised compounds were confirmed by 
1
H NMR, 
13
C NMR and IR spectroscopy, and mass spectrometry. Also, the purity of these compounds 
were determined to be >95% pure by HPLC. 
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Scheme 1- Synthesis of methoxy and 4-thiocarbonyl analogues of quercetin 
 
(i) 15% KOH, room temperature to 90 
o
C, overnight; (ii) Dry toluene, Lawesson’s reagent, 110 oC, 4 h; (iii) 
Dry DCM, BBr3, 40 
o
C, overnight. 
Scheme 2- Synthesis of luteolin and its methoxy and 4-thiocarbonyl analogues 
 
(i) Pyridine, 75 
o
C, 1 h; (ii) Pyridine, KOH, 50-75 
o
C, 2 h; (iii) Glacial acetic acid, 1% H2SO4, 90-110 
o
C, 1 h, 
(iv) Dry DCM, BBr3, 40 
o
C, overnight; (v) Dry toluene, Lawesson’s reagent,110 oC, 4 h; (vi) Dry DCM, BBr3, 
40 
o
C, overnight. 
 
Figure 1. The quercetin and luteolin derivatives synthesised and evaluated in this study.  
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2.2 Antiangiogenic studies 
2.2.1 Scratch assay 
 Following the synthesis of the quercetin and luteolin derivatives (2-4 and 9-12, respectively), 
their antiangiogenic properties were assessed in vitro. The antiangiogenic potencies of these 
compounds were assessed at the cellular level using human umbilical endothelial vascular cells 
(HUVECs) using a well-established in vitro model [17,18]. The migration of endothelial cell is a 
key step in the process of angiogenesis [19]. HUVECs show very high rates of migration when 
stimulated with the chemokine VEGF. Therefore, the antiangiogenic potencies of these 
derivatives were assessed through their ability to inhibit the VEGF-induced migration of 
HUVECs using an in vitro scratch/wound healing assay [20]. 
The effects of quercetin, luteolin and their derivatives on the inhibition of the chemotactic 
motility of HUVECs are shown in Figures-2 and 3. All compounds were initially screened at 10 
µM concentration. However, changes in the cell morphology were observed in the presence of 
luteolin (Figure-3) as well as the 4-thio derivatives of quercetin (4) and luteolin (12) (data not 
shown) at this concentration, which indicates an undesirable level of toxicity. Hence, 
compounds 10, 4 and 12, along with quercetin (for comparison), were tested at a lower (1 µM) 
concentration. Figure-2 shows the effects of quercetin and its derivatives on VEGF-induced cell 
migration. Quercetin at 10 µM exhibited 74% inhibition of VEGF-induced cell migration, and 
this is in agreement with previous reports [13]. Also, when tested at 1 µM concentration, 
quercetin still retained antiangiogenic properties with 54% inhibition of VEGF-stimulated 
migration. The newly synthesised 4-thio derivative of quercetin (4) displayed 47% inhibitory 
effect at 1 µM concentration, which is comparable to that of quercetin at the same concentration. 
Interestingly, the methoxy derivative of quercetin (2) at 10 µM concentration showed 86% 
inhibition of VEGF-stimulated migration whereas its 4-thio analogue (3) at 10 µM concentration 
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displayed 63% inhibition. Among quercetin and its derivatives, the inhibitory effect observed is 
in the order of compound-2≥compound-1>compound-3>compound-4. Figure-3 shows the 
profile for luteolin and its derivatives. Luteolin at 10 µM displayed undesirable morphological 
changes, however such observation has not been reported in the previous study [14]. At 1 µM 
concentration, luteolin exhibited 86% inhibition of VEGF-stimulated migration. The new 4-thio 
derivative of luteolin (12) showed statistically significant inhibition of VEGF-stimulated 
migration at 1 µM. The methoxy derivative of luteolin (9) and its 4-thio analogue (11) at their 
10 µM concentration exhibited 58% and 36% inhibition of VEGF-stimulated migration 
respectively. Among luteolin and its derivatives, the inhibitory effect observed is in the order of 
compound-10>compound-9>compound-11>compound-12. 
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Figure 2. Effects of quercetin and its derivatives on VEGF-mediated cell migration in an in vitro scratch assay. A- 
Representative images of scratch assay of HUVEC with the treatments, -ve control- without VEGF, +ve control- 
with VEGF (10 ng/mL), quercetin (1) [10 µM + 10 ng/mL VEGF], quercetin (1) [1 µM + 10 ng/mL VEGF], 
thioquercetin (4) [1 µM + 10 ng/mL VEGF], methoxyquercetin (2) [10 µM + 10 ng/mL VEGF], 
thiomethoxyquercetin (3) [10 µM + 10 ng/mL VEGF]. The images were acquired at 10X magnification, size bar 50 
µM. Dashed lines represent the margins of the initial scratch, area covered by HUVEC after 12 h was quatified 
using ImageJ software. B- Bar chart represent the quantification of the inhibitory effect of quercetin and its 
derivatives on VEGF stimulated  migration, expressed as percentage of the scratched area covered by HUVEC after 
12 h migration and normalized to presence/absence of VEGF (100% and 0% for VEGF and VEGF-free medium, 
respectively). The results for compound-4 at 10 µM is not reported as signs of toxicity were observed for that 
compound at 10 µM concentration.  Data are expressed as mean ± standard error of the mean (SEM), n = 3. 
Statistical significance was estimated with respect to the +ve control by one-way ANOVA, followed by 
Bonferroni’s post hoc test (ns = nonsignificant; *, p < 0.05, **, p < 0.01, ***, p < 0.001,****,  p < 0.0001).  
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Figure 3. Effects of luteolin and its derivatives on VEGF-mediated cell migration in an in vitro scratch assay. A- 
Representative images of scratch assay of HUVEC with the treatments, -ve control- without VEGF, +ve control- 
with VEGF (10 ng/mL), luteolin (10) [1 µM + 10 ng/mL VEGF], thioluteolin (12) [1 µM + 10 ng/mL VEGF], 
methoxyluteolin (9) [10 µM + 10 ng/mL VEGF], thiomethoxyluteolin (11) [10 µM + 10 ng/mL VEGF]. The 
images were acquired at 10X magnification, size bar 50 µM. Dashed lines represent the margins of the initial 
scratch, area covered by HUVEC after 12 h was quatified using ImageJ software. B-Bar chart represent the 
quantification of the inhibitory effect of luteolin and its derivatives on VEGF stimulated migration, expressed as 
percentage of the scratched area covered by HUVEC after 12 h migration and normalized to presence/absence of 
VEGF (100% and 0% for VEGF and VEGF-free medium, respectively). The results for compounds-10 and 12 at 10 
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µM are not reported as signs of toxicity were observed for those compounds at 10 µM concentration. Data are 
expressed as the mean ± standard error of the mean (SEM), n = 3. Statistical significance was estimated with 
respect to the +ve control by one-way ANOVA, followed by Bonferroni’s post hoc test (ns = nonsignificant; *, p < 
0.05, ***, p < 0.001, ****, p < 0.0001).  
2.2.2 Western blotting 
 Having observed the inhibition of VEGF induced cell migration in the presence of quercetin 
and the luteolin derivatives, their possible mechanisms of angiogenesis inhibition were 
elucidated using Western blotting. VEGF signalling via the phosphorylation of VEGFR2 
promotes cell growth and survival [21]. Tyr1175 is a major phosphorylation site of VEGFR2 
and its phosphorylation triggers a downstream signalling cascade, which ultimately results in 
increased endothelial cell proliferation, migration and vascular permeability [22]. Thus, 
quercetin, luteolin and their derivatives that showed significant inhibition of the VEGF 
stimulated cell migration in the in vitro scratch assay were investigated for their effects on 
VEGFR2 autophosphorylation at Tyr1175 site in HUVEC’s.  
In general, the results obtained from the Western blotting analysis (Figure-4) mirror the results 
obtained with the scratch assay. VEGF (10 ng/mL) [+ve control] significantly promoted the 
levels of phosphorylated VEGFR2 (P-VEGFR2) in comparison to the –ve control without 
VEGF stimulation. In the case of quercetin and its derivatives, quercetin (1) at both 10 µM and 
1 µM, its methoxy derivative (2) and thiomethoxy derivative (3) at 10 µM all showed significant 
reduction in the levels of P-VEGFR2, whereas, such reduction in the levels of P-VEGFR2 was 
not displayed by the 4-thio derivative of quercetin (4) at 10 µM concentration. As mentioned 
earlier, the order of inhibitory effect correlated well with the scratch assay results, i.e. 
compound-2≥compound-1>compound-3>compound-4. In the case of luteolin and its derivatives 
only luteolin at 1 µM concentration displayed significant reduction in the P-VEGFR2 levels 
while its methoxy and 4-thiomethoxy derivatives (9 and 11) did not show significant inhibition 
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on the VEGF-induced autophosphorylation of VEGFR2. These results suggest that compounds-
1, 2, 3 and 10 mediates their antiangiogenic effects via the suppression of VEGFR2 
phosphorylation. 
   
 
Figure 4. A-Representative Western blot images of HUVEC proteins with the treatments, -ve control- without 
VEGF, +ve control- with VEGF (10 ng/mL), quercetin (1) [10 µM + 10 ng/mL VEGF], quercetin (1) [1 µM + 10 
ng/mL VEGF], thioquercetin (4)  [1 µM + 10 ng/mL VEGF], methoxyquercetin (2)  [10 µM + 10 ng/mL VEGF], 
thiomethoxyquercetin (3)  [10 µM + 10 ng/mL VEGF], luteolin (10) [1 µM + 10 ng/mL VEGF], methoxyluteolin 
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(9) [10 µM + 10 ng/mL VEGF], thiomethoxyluteolin (11)  [10 µM + 10 ng/mL VEGF]; actin was used as a loading 
control. B- Bar chart represents the quantification of the inhibitory effect of quercetin, luteolin and its derivatives 
on VEGF induced phosphorylation. Data are expressed as mean ± standard error of the mean (SEM), n = 3. 
Statistical significance was estimated vs the +ve control by one-way ANOVA, followed by Bonferroni’s post hoc 
test (#-significant with respect to –ve control, ns = nonsignificant; *, p < 0.05, ***, p < 0.001, ****, p < 0.0001).  
2.3 Molecular docking 
Molecules that interfere with the VEGF/VEGFR signalling pathway typically work by either 
blocking the VEGF ligand directly or by inhibiting its receptor VEGFR2. Hence, molecular 
docking studies were conducted to elucidate the potential molecular interactions between 
quercetin and luteolin derivatives and both VEGFR2 and VEGF. The derivatised molecules 
were docked sequentially into the respective binding sites, using the X-ray crystallographic 
structures of VEGFR2 receptor (PBD code-1YWN) and VEGF (PBD code-1VPP). The docking 
procedure was first validated by re-docking the extracted co-crystallised ligand of VEGFR2 (4-
amino-furo[2,3-d]pyrimidine) into the prepared protein to be used for docking. The RMSD 
between the docked conformation generated by the program and the native co-crystallized 
ligand conformation was found to be 0.10 Å, well within the 2 Å grid spacing used for docking, 
indicating that the docking procedure to be used was reliable and valid. Furthermore, the 
interactions between the docked ligand and the receptor mimicked those observed in the crystal 
structure of the same. 
Interactions with VEGFR2: The results of ligand-directed docking into the ATP-binding site of 
VEGFR2 are summarised in Table-S1 (see supporting information) in decreasing order of the 
ligand binding affinities, as determined by their docking scores. The binding modes of 
quercetin, luteolin and their derivatives with VEGFR2 are depicted in Figure-5. The quercetin 
and luteolin derivatives have shown potential interactions with the key residues, Glu-883, Lys-
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866 and Cys-917 of VEGFR2 through hydrogen bonding. The docking scores suggest that 
compounds 2, 10 and 3 have greater binding affinity towards VEGFR2.  
Interactions with VEGF: The results of automated docking procedure with VEGF are 
summarised in Table-S2 (see supporting information) in decreasing order of the ligand binding 
affinities, as determined by their docking scores. The binding modes of quercetin, luteolin and 
their derivatives with VEGF are depicted in Figure-6. The quercetin and luteolin derivatives 
have also shown potential interactions with the key residues, Leu-32V, Gly-59V and Asp-34W 
residues of VEGF through hydrogen bonding. Compounds 9, 2 and 11 showed greater binding 
affinity towards VEGF. 
Among these compounds, the methoxy derivative of quercetin (compound-2) has shown higher 
binding affinities towards both VEGFR2 and VEGF. This compound was found binding to the 
ATP binding site of VEGFR2 through the formation of hydrogen bonds to the ‘hinge’ region 
residues Cys-917-N (2.98 Å), Cys-917-O (2.92 Å), Glu-883-O (2.61 Å) and Lys-866-N (2.94 Å) 
residue of the hydrophobic pocket, and also through hydrophobic interactions (Figure-5). The 
major interactions of compound-2 with VEGF are Leu-32V-N (2.98 Å), Gly-59V-N (2.79, 2.91 
Å), and Asp-34W-N (3.13 Å) (Figure-6). In general, the analysis of molecular docking results 
revealed that compound-2 possibly acts as an inhibitor of VEGFR2 and its binding potency 
relies on strong hydrophobic interactions between the compound and the binding site of the 
receptor. Also, the docking studies suggested that the higher binding affinities of compound-2 
towards both VEGFR2 and VEGF could possibly be the reason for its antiangiogenic activity as 
observed in both the scratch assay and Western blotting. Similarly, the weaker antiangiogenic 
activities of the 4-thio derivatives of quercetin and luteolin could be because of their poor 
binding affinities towards VEGFR2 and VEGF. This could be further verified in future studies 
by utilising a cell free protein kinase assay of VEGFR2.  
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Figure 5. Docking modes of quercetin (1) (A), methoxy quercetin (2) (B), thiomethoxy quercetin (3) (C), 
thioquercetin (4) (D), luteolin (10) (E), methoxy luteolin (9) (F), thiomethoxy luteolin (11) (G), thioluteolin (12) 
(H) with VEGFR2. 
 
  
GLU-883
LYS-866
2.75 Å
3.09 Å 3.14 Å
CYS-917
2.73 Å
GLU-883
3.04 Å
2.86 Å
2.84 Å
LEU-32 W
GLY-30 V
LEU-32 V
2.98 Å
3.19 Å
3.08 Å
GLY-59 W
2.87 Å
2.95 Å
2.73 Å
GLY-30 W
3.19 Å ASP-34 W
GLY-59 V
LEU-32 V
3.13 Å
2.79 Å
2.98 Å
2.91 Å
G H 
A B 
18 
 
                
 
           
 
ASP-34 W
LEU-32 V
2.98 Å
3.10 Å
CYS-37 W
GLY-59 W
GLU-30 V
3.05 Å
2.89 Å
2.81 Å
2.55 Å
2.90 Å
GLU-30 W
THR-31 W
2.87 Å
ASP-56 W
GLY-59 W
LEU-32 V
2.88 Å
2.87 Å
2.99 Å
2.93 Å
2.94 Å
ASP-34 W
GLY-59 V
LEU-32 V
3.08 Å
2.82 Å
2.90 Å
C D 
E F 
19 
 
                       
 
Figure 6. Docking modes of quercetin (1) (A), methoxy quercetin (2) (B), thiomethoxy quercetin (3) (C), 
thioquercetin (4) (D), luteolin (10) (E), methoxy luteolin (9) (F), thiomethoxy luteolin (11) (G), thioluteolin (12) 
(H) with VEGF. 
2.4 Membrane perturbation (probed by DSC) 
A recent paper by Ingólfsson et al. has provided new insight into how the biological effects of 
flavonoids might be explained [23]. The authors suggest that many of the biological activities 
triggered by flavonoids (more specifically, activation of certain membrane proteins) might, in 
fact, be the result of flavonoid-induced perturbation of biological membranes, rather than a 
direct ligand-receptor effect. The authors do not exclude the possibility of direct binding, but 
recommend ruling out bilayer effects first. Therefore, the 6 compounds (1-3 and 9-11), which 
showed VEGF/VEGFR mediated antiangiogenic activity (in the scratch assay and Western 
blotting) in our study, were further investigated for a possible lipid interaction (bilayer effect) 
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with a dipalmitoylphosphatidylcholine bilayer [DPPC (lipid)] model using differential scanning 
calorimetry (DSC). In order to validate our system, genistein, which has been reported to perturb 
biological membranes by Ingolfsson et al. and has a structural similarity with our panel of 
compounds, was used as a positive control.  
Dipalmitoylphosphatidylcholine (DPPC) alone (i.e. in the absence of genistein or any 
compounds) showed a pre transition (Tp) centered at 36.25 °C and a main transition (Tm) at 
41.31 °C. These data for the pure lipid system are in good agreement with previous reports 
[24,25] (Figure-7). Addition of genistein to the DPPC system showed perturbation of this lipid 
bilayer, as evidenced by a significant lowering of the Tm (from 41.23 °C to 40.89 °C (at 60 μM) 
and to 40.51 °C (at 100 μM)), as reported in Table-1 and Figure-7. No changes were observed 
with the ΔH of the main transition temperature (ΔHm) peak, but the Tp peak broadened at 10 μM 
and became undetectable at 60 μM and 100 μM. The lowest concentration of genistein at which 
a membrane effect was observed (60 μM ) was in line with the concentrations at which 
genistein’s bilayer effect had been reported by Ingolfsson et al [23], which indicated that the 
experimental system was fit for purpose and could be used to assess the potential bilayer effect 
of our compounds. 
Quercetin and its derivatives: Unlike genistein, quercetin and its derivatives did not affect the 
Tm at the concentration for which antiangiogenic activity was reported (10 μM) (see supporting 
information) and, indeed, no significant effect was evident at 10 times that concentration (100 
μM) (see Table-1 and Figure-7). No change was observed for ΔHm but the Tp peak was affected 
(Tp was lowered along with the peak broadening). Others have suggested that the Tp is highly 
sensitive to the presence of other molecules in the phospholipids and that changes in the pre-
transition of  DSC profile cannot be attributed to any specific molecular changes [26]. Several 
studies have been reported on the interactions of quercetin with bilayer lipid membranes [27,28], 
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mainly the study by Sinha et al. in which quercetin was reported to affect biological membranes 
primarily at concentrations 250 fold higher than those for which we are reporting activity [29]. 
Luteolin and its derivatives: When luteolin (10), methoxy luteolin (9) and thiomethoxy luteolin 
(11) were analysed, no changes in the DSC profile of DPPC was observed at the biologically 
active concentrations nor at 10 times that concentration.  
Taken together, these results indicate that the antiangiogenic activity observed for the 
compounds studied herein is likely to be mediated via an interference with the VEGF/VEGFR 
signalling pathway, as evidenced by the Western blotting and computational studies, rather than 
being the result of membrane perturbation. This statement is certainly true for luteolin and its 
derivatives, for which no interactions were observed. The subtle membrane effect observed for 
quercetin and its derivatives does not appear to be sufficiently significant to explain the 
biological effects and dismiss a specific interaction with the VEGF/VEGFR system.  
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Figure 7. Representative DSC profiles of  DPPC MLV’s illustrating the effect in the presence of (A) Genistein at 10 
µM (G-10 µM), 60 µM (G-60 µM), and 100 µM (G-100 µM) in comparison with DPPC alone; (B) Quercetin and its 
derivatives (at 10 times the concentration at which antiangiogenic effects were observed): compound-1 at 100 µM, 
compound-2 at 100 µM, compound-3 at 100 µM in comparison with genistein at 100 µM and DPPC alone; (C) 
Luteolin and its derivatives (at 10 times the concentration at which antiangiogenic effects were observed): 
compound-9 at 100 µM, compound-10 at 10 µM, compound-11 at 100 µM in comparison with genistein at 100 µM 
and DPPC alone. 
Table 1. Thermodynamic parameters obtained by DSC for the interaction of DPPC with 
compounds 1-3 and 9-11
a 
Compound 
Concentration 
(µM) 
Tp  
(°C) 
Tm  
(°C) 
ΔHm  
 (KJ/mol) 
 
Positive control 
0
b
  36.25 ± 0.33 41.31±0.01 23.03 ± 0.56 
10 35.28 ± 0.10
**
 41.23 ± 0.01 23.31 ± 0.89 
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Genistein 60  - 40.89 ± 0.09
*
 22.90 ± 0.89 
100  - 40.51 ± 0.12
**** 
23.10 ± 0.78 
 
Compound-1 
 
0
b
 36.25 ± 0.33 41.31±0.01 23.03 ± 0.56 
10  35.65 ± 0.18
*
 41.28 ± 0.02 23.09 ± 0.86 
100  - 41.26 ± 0.01 22.98 ± 0.45 
 
Compound-2 
 
0
b
 36.25 ± 0.33 41.31±0.01 23.03 ± 0.56 
10  35.58 ± 0.15
*
 41.29 ± 0.01 22.80 ± 0.76 
100 - 41.15 ± 0.01 22.91 ± 0.55 
Compound-3 
0
b
 36.25 ± 0.33 41.31±0.01 23.03 ± 0.56 
10  35.70 ± 0.05
*
 41.25 ± 0.01 23.08 ± 1.04 
100  - 41.20 ± 0.01 23.28 ± 0.32 
 
Compound-9 
 
0
b
  36.25 ± 0.33 41.31±0.01 23.03 ± 0.56 
10  36.52 ± 0.03 41.26 ± 0.02 22.56 ± 0.65 
100  36.54 ± 0.02 41.30 ± 0.03 22.35 ± 0.46 
 
Compound-10 
 
0
b
  36.25 ± 0.33 41.31±0.01 23.03 ± 0.56 
10  36.43 ± 0.04 41.30 ± 0.01 22.79 ± 0.84 
100  - 41.32 ± 0.01 21.68 ± 0.32 
Compound-11 
0
b
 36.25 ± 0.33 41.31±0.01 23.03 ± 0.56 
10  36.62 ± 0.05 41.33 ± 0.01 23.81 ± 0.97 
100  36.61 ± 0.01 41.31 ± 0.01 23.34 ± 0.73 
a
Data are expressed as the mean ± standard error of the mean (SEM), n = 3. 
b
0 µM corresponds to plain DPPC 
(without any additive). Tp- Pre-transition temperature, Tm- Main transition temperature, ΔHm- Enthalpy change of 
the main transition peak. Statistical significance was estimated vs the control (DPPC alone, i.e. 0 µM) by one-way 
ANOVA, followed by Bonferroni’s post hoc test (*p < 0.05, **p < 0.01 and ****p < 0.0001).  
2.5 Antiproliferative activity  
The flavonoids are known to exhibit a direct antiproliferative effect on various tumour cells [6] 
including hormone dependent cancers such as MCF-7 breast cancer cell line. Therefore, we 
considered MCF-7 as an appropriate model to assess the antiproliferative activity of the 
compounds prepared herein. Hence, in this study, the direct inhibitory effects of quercetin and 
luteolin derivatives were determined against the breast cancer cell line MCF-7 (wild type) and 
its doxorubicin-resistant cell line MCF-7/DX to compare their concentrations that are required 
to elicit the direct anticancer activity and the antiangiogenic activity. Cell viabilities were 
determined in the presence and the absence of quercetin, luteolin and their derivatives by MTT 
assay [30] after 72 h incubation. The cytotoxicity profiles and the IC50 values of these 
compounds are shown in Figure-8 and Table-2 respectively. 
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Among quercetin and its derivatives, only compound-1 was found to be antiproliferative with 
IC50 values of 13.7 ± 0.61 µM and 80.4 ± 1.79 µM against MCF-7 cell line and MCF-7/DX cell 
line respectively. The methoxy and the 4-thio derivative, compounds-2 and 4 respectively 
displayed their antiproliferative activity at concentrations greater than 100 µM, whereas the 4-
thiomethoxy derivative, compound-3 did not demonstrate any cytotoxicity below 250 µM 
concentration. Thus, the antiproliferative activities of quercetin and its derivatives are in the 
order of compound-1>compound-4>compound-2>compound-3. Among luteolin and its 
derivatives, compounds-10 and 12 were found to be active with IC50 values of 21.6 ± 0.81 µM 
and 27.3 ± 1.55 µM respectively against MCF-7 cell line and 81.1 ± 1.79 µM and 75.9 ± 3.08 
µM respectively against MCF-7/DX cell line. However, compounds 9 and 11 did not 
demonstrate any antiproliferative activity below 250 µM concentration. Therefore, the 
antiproliferative activities of luteolin and its derivatives are in the order of compound-
10≥compound-12>compound-9≡compound-11. In general, the antiproliferative activities of 
these compounds suggest that the methoxy and the thiomethoxy derivatives are 10-15 fold less 
active than their parent compounds.  
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Figure 8. Dose-dependent cytotoxicity curves of quercetin (1), thioquercetin (4), methoxy quercetin (2) and 
thiomethoxy quercetin (3) (A) against MCF-7 (B) against MCF-7/DX. Dose-dependent cytotoxicity curves of 
luteolin (10), thioluteolin (12) methoxyluteolin (9) and  thiomethoxyluteolin (11) (C) against MCF-7 (D) against 
MCF-7/DX. Data are expressed as the mean ± standard error of the mean (SEM), n = 3. 
Table 2- IC50 values of quercetin, luteolin and their derivatives. 
Chemical 
structure 
Compound Substitution IC50 in MCF-7 IC50 in MCF-7/DX 
 1 R
1,2,3,4,5
= OH, X= O 13.7 ± 0.61 µM 80.4 ± 1.79 µM 
4 R
1,2,3,4,5
= OH, X= S 102.6 ± 5.36 µM 139.3 ± 6.89 µM 
2 R
1,2,3,4,5
= OMe, X= O 140 ± 1.63 µM 245.1 ± 2.53 µM 
3 R
1,2,3,4,5
= OMe, X= S >250 µM >250 µM 
 10 R
1,2,3,4
= OH, X= O 21.6 ± 0.81 µM 81.1 ± 1.79 µM 
12 R
1,2,3,4
= OH, X= S 27.3 ± 1.55 µM 75.9 ± 3.08 µM 
9 R
1,2,3,4
= OMe, X= O >250 µM >250 µM 
11 R
1,2,3,4
= OMe, X= S >250 µM >250 µM 
2.6 Considerations of the structure-activity relationships (SARs) 
Comparison of the antiangiogenic activities and antiproliferative activities of quercetin, luteolin 
and their derivatives has led to identification of the key structural features that are specific for an 
enhanced and a selective antiangiogenic activity. Comparison of the antiangiogenic activities of 
underivatised quercetin (1, bearing 5 hydroxyls, 4-C=O) with underivatised luteolin (10, bearing 
4 hydroxyls, 4-C=O) indicates that luteolin without the C-3 hydroxyl has a higher 
antiangiogenic potential (86% versus 54% inhibition of VEGF stimulated migration at 1 µM 
concentration). This observation is consistent with the Western blotting analysis, which showed 
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increased inhibition of autophosphorylation of VEGFR2 in presence of luteolin (1 µM). 
Docking studies also suggested greater binding affinity of luteolin (docking score-6.87) with 
VEGFR2 than quercetin (docking score-6.56). These observations suggest that the C-3 hydroxyl 
is not important for the antiangiogenic activity. However, for their methoxy derivatives (-OMe 
and 4-C=O), it was observed that the methoxy derivative of quercetin containing a C-3 methoxy 
group has a greater potency to inhibit VEGF stimulated migration (86% at 10 µM) through the 
inhibition of VEGF mediated autophosphorylation at Tyr-1175 site than the methoxy analogue 
of luteolin (9) as well as the hydroxy analogues quercetin and luteolin. Docking studies also 
indicated the highest binding affinity of compound-2 with both VEGFR2 and VEGF, and also it 
was observed that the enhanced antiangiogenic activity of compound-2 is due to the enhanced 
hydrophobic interactions formed by of C-3 -OMe group with the VEGFR2. This demonstrates 
that the presence of a C-3 -OMe group is beneficial for the antiangiogenic activity.  
Similarly, comparison of the antiangiogenic activities of compounds containing the 4-C=O 
functionality (1, 2, 9 and 10) with the derivatives containing the 4-C=S functionality (3, 4, 11 
and 12) indicated that replacement of the 4-C=O group with a 4-C=S resulted in a weaker in 
vitro inhibition of VEGF-stimulated migration, especially for 4-C=S compounds with the free 
hydroxyl groups (4 and 12). Hence, conversion of the 4-C=O to 4-C=S group is detrimental to 
the antiangiogenic activities of both quercetin and luteolin. This observation is further supported 
by the Western blotting studies that illustrate very poor inhibition of autophosphorylation of 
VEGFR2, and also by the molecular docking studies that show weaker interactions with 
VEGFR2 and VEGF, by these 4-C=S derivatised compounds. Collectively, these results suggest 
that the 4-C=O moiety is crucial for antiangiogenic activity. 
From the comparison of the antiproliferative and the antiangiogenic activities of quercetin, 
luteolin and their derivatives, it is interesting to note that the derivatives with higher 
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antiangiogenic properties were generally less cytotoxic than those with lower antiangiogenic 
properties. This would be an attractive feature of these derivatives for use in future clinical 
development as they could potentially be used for their anti-angiogenic properties at 
concentrations significantly lower than those required for a direct anticancer activity. Thus 
comparison of the antiproliferative activities of quercetin and luteolin with their methoxy, 4-
thiomethoxy and 4-thiohydroxy derivatives illustrates that methylation of the free hydroxyls and 
replacement of the 4-C=O group with a 4-C=S group decreases the antiproliferative activity. In 
the case of quercetin, methylation of the hydroxyl group resulted in a 10-18 fold decrease in the 
antiproliferative potency. A similar trend was observed in the case of luteolin where an 
approximately 11 fold decline in antiproliferative activity was observed for its methoxy 
derivative. Replacement of the 4-C=O group with a 4-C=S group in the case of quercetin has 
also shown a detrimental impact on the antiproliferative activity with the 4-thio derivative 
showing about 8 fold less reactivity than quercetin. However, in the case of luteolin, the 
conversion of the 4-C=O group to the 4-C=S group has not impacted on the antiproliferative 
property with both luteolin and its 4-thio derivative exhibiting similar cytotoxicity profiles. This 
suggests that methylation of the free hydroxyl groups in flavonoids allows selective 
antiangiogenic activity. Figure-9 presents the SAR observed for the quercetin and luteolin 
derivatives. 
Overall, methoxyquercetin (2) and luteolin (10) possess higher potency to prevent VEGF driven 
HUVEC migration at a 10 and 20 fold lower concentration respectively than the concentration 
that is required to directly inhibit the in vitro proliferation of tumour cells. This could be 
attributed to the high degree of selectivity of this compound for the inhibition of VEGFR2 
versus a range of other kinases [31].  
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As the clinical outcomes of the current antiangiogenic therapy and preclinical studies have 
suggested the need for co-administration of the inhibitors with chemotherapeutics, for continual 
constraint of angiogenesis [32–34], molecules with an appropriate balance of high potency 
against VEGFR2 and minimal toxicity are preferred. Therefore, with the view of developing 
antiangiogenic agents for cancer therapeutics and combination therapy, our present work 
suggests compound-2 and compound-10 as potential leads for further optimisation and 
development. 
Figure 9. General SAR of quercetin and luteolin derivatives 
3 CONCLUSION 
In conclusion, we have synthesised the methoxy and 4-thio derivatives of quercetin and luteolin 
and evaluated their resulting antiangiogenic and antiproliferative potencies, alongside quercetin 
and luteolin. As part of this programme we have demonstrated the impact of subtle structural 
modifications such as methylation and 4-thio conversion on the antiangiogenic and 
antiproliferative properties of quercetin and luteolin. Comparison of their antiangiogenic 
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activities has led to identification of key structural features required for the antiangiogenic 
activities. It was found that the 4-C=O functionality is crucial for the antiangiogenic activity and 
also methylation of the free hydroxyl groups provides the benefit of potential antiangiogenic 
activity with low cytotoxicity. Also, analysis of bilayer membrane interactions of the active 
compounds suggests that bilayer effects do not play a significant role in the biological 
mechanism of action at the concentrations tested, especially for luteolin and its derivatives. 
Among quercetin, luteolin and their derivatives, compound-2 and compound-10 were found to 
potentially inhibit the in vitro VEGF induced cell migration with low cytotoxicity. In addition, 
the molecular docking studies indicated that compound-2 and compound-10 possess high 
binding affinities towards VEGF and VEGFR2. Overall, compound-2 and compound-10 exhibit 
an appropriate balance of high antiangiogenic activity and minimal toxicity. Therefore, they 
have been identified as the most promising flavonoid templates from our programme of study 
for further development as antiangiogenic agents.  
4 EXPERIMENTAL SECTION 
4.1 Materials and Methods 
Chemicals and Reagents: All chemicals were purchased from Sigma-Aldrich unless specified. 
2-hydroxy-4,6-dimethoxyacetophenone was purchased from Alfa Aesar, UK and quercetin was 
purchased from Sigma-Aldrich, UK. Solvents were purchased from Fisher Scientific, UK and 
Sigma Aldrich, UK. 1H-NMR and 13C-NMR spectra were recorded in either deuterated 
chloroform (CDCl3), deutereated dimethyl sulfoxide (DMSO-d6) using a Bruker DPX 400 (400 
MHz) spectrometer. Mass spectrometry data were recorded on a Thermo Fisher LTQ Orbitrap 
XL instrument. A HPLC (Agilent-1100 series) equipped with Column: C-18 (ACE-221-2546; 
4.6 mm X 250 mm; 5 µm); 1.0 mL/min flow rate; 20 min gradient of 1% acetic acid in 
acetonitrile [organic mobile phase (A)] and 1% acetic acid in water [aqueous mobile phase (B)] 
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from 5% A at 0 min, 20% A at 2min, 40% A at 6 min, 60% A at 8 min, 95% A at 10 min, 5% A 
at 20 min, at 258 nm was used to determine the purity of all the synthesised compounds. 
Cell line and Culture: HUVECs were purchased from ECACC and cultured in EGM-2 medium. 
MCF-7 (ER +ve breast cancer cell line, wild type) and MCF-7/DX (ER +ve breast cancer cell 
line, doxorubicin resistant type) were provided by Tenovus centre for Cancer research (Cardiff, 
UK). Both MCF-7 and MCF-7/DX cells were cultured in RPMI 1640 supplemented with 5% 
fetal bovine serum. All the culture media and other reagents were obtained from Lonza, UK. 
Bovine serum albumin (BSA) was purchased from Sigma Aldrich, UK. Recombinant human 
VEGFR-A165 was purchased from Peprotech, UK. The primary antibodies directed against 
phosphorylated tyrosine-1175 site in the VEGFR2 (KDR) was purchased from Cell signalling, 
UK. The primary antibody directed against total VEGFR2 was purchased from Santa Cruz 
Biotechnology, UK and the primary antibody directed against actin was purchased from Abcam, 
UK. Horseradish peroxidase-conjugated secondary antibody was purchased from Abcam, UK. 
Enhanced chemiluminescences (ECL) detection solutions were purchased from Bio-Rad, UK. 
PVDF membrane was purchased from Bio-Rad, UK. Reagents for Phosphate buffered saline 
(PBS) for cell culture were purchased from Sigma Aldrich, UK. PBS (pH 7.4) was freshly 
prepared in lab and solution pH was checked before used. Scratch assay images were captured 
using 1.3M microscope digital eyepiece camera. ImageJ software was used to quantify the cell 
migration. 
The stock solutions of the test compounds (10 mg/mL) were prepared in sterile DMSO and 
ethanol (1:1 v/v). These stocks were then appropriately diluted with the complete culture 
medium and the ethanol and DMSO levels were maintained below 1% in the test concentrations. 
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Statistics analysis: Statistical analysis was carried out against the control groupby one-way 
ANOVA followed by Bonferroni’s post hoc test using GraphpadPrism 6. Statistical significance 
value was set at p<0.05.  
33 
 
4.1.1 Synthesis of methoxy and 4-thio methoxy quercetin (2-4) 
4.1.1.1 Synthesis of 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-4H-chromen-4-one (2) 
Quercetin (1) (1g, 3.30 mmol) was dissolved in KOH (15%, 10 mL) at ambient temperature. 
Dimethyl sulfate (2.29 g, 1.7 mL, 18.15 mmol, 5.5 eq., d=1.33 g/mL) was added slowly over 10 
min and the reaction was stirred at ambient temperature for 1 h. After 1 h, further dimethyl 
sulfate (5.5 eq.) and KOH (15%, 10 mL) were added and the mixture was heated to 90 
o
C. After 
3 h, further dimethyl sulfate (5.5 eq.) and KOH (15%, 10 mL) were added and the reaction was 
stirred overnight at 90 
o
C. KOH (15%, 15 mL) was then added and the reaction was stirred for 
another 5 h at 90 
o
C. The reaction was cooled to room temperature, and acidified to pH 5 by the 
addition of2 M HCl (20 mL). The precipitate was filtered and washed with water. The 2-(3,4-
dimethoxyphenyl)-3,5,7-trimethoxy-4H-chromen-4-one (2) was obtained as an off white solid in 
a pure form after purification by column chromatography [Solvent system: EtOAc (100%)]. 
Yield: 60%; m.p: 155-7 
o
C (lit [35]-150-52 
o
C);
1
H NMR: (DMSO-d6,400 MHz)  3.88, 3.90, 
3.96 (15H, s, -OCH3), 6.34 (1H, s, H-6), 6.50 (1H, s, H-8), 6.97 (1H, d, J= 8.0 Hz, H-5’), 7.69 
(1H, d, J= 8.0 Hz, H- 6’), 7.71 (1H, s, H-2’); 13C NMR: (DMSO-d6, 100 MHz)  56.3 (4 x-
OCH3), 59.9 (-OCH3), 92.3 (C8), 95.8 (C6), 109.4 (C10), 110.7 (C2’), 111.5 (C5’), 121.6 (C6’), 
123.7 (C1’), 141.3 (C3), 148.8 (C4’), 150.8 (C3’), 152.6 (C2), 158.9 (C9), 161.3 (C5), 164.1 
(C7), 174.0 (C=O); IR νmax[cm
-1
]: 1651(C=O, ν, s), 1291 (-OCH3, ν, s), 1097 (C-O, ν, m); m/z 
(FTMS+ESI):  M+H (C20H21O7) requires 373.1282, found 373.1277. HPLC purity: 96.1% 
4.1.1.2 Synthesis of 2-(3,4-dimethoxyphenyl)-3,5,7-trimethoxy-4H-chromene-4-thione (3) 
2-(3,4-Dimethoxyphenyl)-3,5,7-trimethoxy-4H-chromen-4-one (2) (0.20 g, 0.53 mmol) was 
dissolved in anhydrous toluene (1 mL), and Lawesson’s reagent (0.21, 0.53 mmol, 1 eq.) was 
added and the reaction was heated to 110 
o
C for 4 h. The reaction mixture was cooled to room 
temperature and concentrated in vacuo. The residue was purified by column chromatography 
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[Solvent system: CHCl3 (100 %)] to obtain the pure 2-(3,4-Dimethoxyphenyl)-3,5,7-trimethoxy-
4H-chromene-4-thione (3) as a brown solid.  
Yield: 65%; m.p: 168-70 
o
C (lit [36]-170 
o
C); 
1
H NMR: (CDCl3, 400 MHz)  3.72 (3H, s, 
OCH3), 3.95, 3.93, 3.07, 4.03 (12H, s, 4 x -OCH3), 6.42 (1H, s, H-6), 6.54 (1H, s, H-8), 7.00 
(1H, d, J= 8.5 Hz, H-5’), 7.78 (1H, d, J= 8.5 Hz, H-6’), 7.86 (1H, s, H-2’); 13C NMR: (CDCl3, 
100 MHz)  56.0 (-OCH3), 58.7 (-OCH3), 92.3 (C8), 96.7 (C6), 110.6 (C2’), 111.6 (C5’), 116.8 
(C10), 122.0 (C6’), 123.2 (C1’), 146.3 (C3), 148.6 (C4’), 149.6 (C3’), 151.2 (C2), 154.4 (C9), 
161.6 (C7), 163.5 (C5), 194.0 (C=S); IR νmax[cm
-1
]: 1351 (C=S, ν, m), 1220 (-OCH3, ν, m) 
1143 (C-O, ν, m); m/z (FTMS+ESI): M+H (C20H21O6S) requires 389.1053, found 389.1055. 
HPLC purity: 96.1% 
4.1.1.3 Synthesis of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromene-4-thione (4) 
2-(3,4-Dimethoxyphenyl)-3,5,7-trimethoxy-4H-chromene-4-thione (3) (0.10 g, 0.257 mmol) 
was dissolved in anhydrous DCM (1 mL). BBr3 (0.35 g, 0.135 mL, 1.413 mmol, 5.5 eq., d=2.60 
g/mL) was added and the reaction was stirred at 40 
o
C overnight. The reaction was cooled to 
room temperature and diluted with water (2 mL). The pH was adjusted to 6 with 5% Na2HPO4 
and the precipitated product was filtered to afford the crude product. The pure product, 2-(3,4-
dimethoxyphenyl)-3,5,7-trihydroxy-4H-chromene-4-thione (4), was obtained as a bright red 
solid after purification by column chromatography [Solvent system: EtOAc (100 %)]. 
Yield: 55%; m.p: 268-70 
o
C (decomposed); 
1
H NMR: (CDCl3, 400 MHz) 6.34 (1H, s, H-6), 
6.54 (1H, s, H-8), 6.92 (1H, d, J = 8.5 Hz, H-5’), 7.71 (1H, d, J = 8.5 Hz, H-6’), 7.76 (1H, s, H-
2’), 8.66 (1H, s, OH), 9.44 (1H, s, OH), 9.91 (1H, s, OH), 11.07 (1H, s, OH), 13.06 (1H, s, OH); 
13
C NMR: (CDCl3, 100 MHz)  93.8 (C8), 100.4 (C6), 111.3 (C10), 115.7 (5’), 115.8 (C2’), 
120.7(C6’), 121.6 (C1’), 142.4 (C3’), 142.7 (C4’), 145.3 (C9), 149.1 (C7), 152.5 (C2), 160.1 
(C5), 163.5 (C3), 181.6 (C=S); IR νmax[cm
-1
]: 1267 (C=S, ν, m), 1147(C-O, ν, m), 3084 (OH, 
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w, b); m/z (FTMS+ESI): M+H (C15H11O6S) requires 319.0271, found 319.0266. HPLC purity: 
99.4% 
4.1.2 Synthesis of luteolin, methoxy luteolin and 4-thiomethoxy luteolin (9-12) 
4.1.2.1 2-Acetyl-3, 5-dimethoxyphenyl 3, 4-dimethoxy benzoate (7) 
1-(2-Hydroxy-4, 6-dimethoxyphenyl) ethanone (5) (1 g, 5.09 mmol) was dissolved in pyridine 
(20 mL) and heated to 50 
o
C. DBU (1 % v/v of pyridine) was added and the mixture was stirred 
at 50 
o
C for 30 min. 3,4-Dimethoxy benzoyl chloride (6) (1.53 g, 7.63 mmol, 1.5 eq.) was added 
slowly over 15 min, the mixture was heated to 75 
o
C and stirred for 1 h. The reaction was cooled 
to room temperature, acidified to pH 5 with 2 M HCl and extracted with EtOAc (2 x 20 mL). 
The organic layers were combined, dried over anhydrous magnesium sulfate and concentrated in 
vacuo to yield the desiredproduct. The pure compound was obtained as a white solid after 
purification by column chromatography [Hexane: CHCl3: EtOAc (3:6:1 v/v/v)]. 
Yield: 60%; m.p: 151-53 
o
C; 
1
H NMR: (CDCl3,,400 MHz)  2.47 (3H, s, -CH3) 3.82 (3H, s, -
OCH3), 3.84 (3H, s, -OCH3), 3.86 (3H, s, -OCH3), 3.96 (3H, s, -OCH3), 6.37 (1H, s, H-4), 6.40 
(1H, s, H-6), 6.91 (1H, d, J= 8 Hz, H-6’), 7.61 (1H, s, H-2’), 7.80 (1H, d, J= 7 Hz, H-5’); 13C 
NMR: (CDCl3, 100 MHz)  29.4 (CH3), 56.0 (-OCH3), 60.3 (-OCH3), 109.7 (C4), 111.1 (C5’), 
112.1 (C2’), 120.6 (C6), 124.3 (C5, C6’), 126.1 (C1’), 140.9 (C2), 143.5 (C3’), 153.5 (C3), 
156.7 (C4’), 163.7 (COO-Ar), 195.5 (COCH3); IR νmax [cm
-1
]: 1713 (C=O, ν, m), 1102 (O-
C=O, ν, m), 1689 (C=O, ν, m), 1246 (-OCH3, ν, s); m/z (FTMS+ESI): M+Na (C19H20O7Na) 
requires 383.1101, found 383.1102. 
4.1.2.2 1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-phenyl propane-1, 3-dione (8) 
The 2-acetyl-3, 5-dimethoxyphenyl 3, 4-dimethoxy benzoate (7) (1.0 g, 2.7 mmol) was 
dissolved in pyridine (15 mL) and  heated to 50 
o
C for 1 h. Anhydrous potassium hydroxide 
[powdered] (0.32g, 5.4 mmol, 2 eq.) was added and the reaction was heated to 75 
o
C . After 1 h, 
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the reaction mixture was cooled to room temperature, acidified to pH 5 with 2M HCl and 
extracted with EtOAc (2 x 5 mL). The organic layers were combined, dried over anhydrous 
magnesium sulfate and concentrated in vacuo to yield the crude 1,3-diketone. The crude 1,3-
diketone was treated with glacial acetic acid to remove the pyridine and the yellow compound 
was used for the next step without purification. 
Yield: 75%; 
1
H NMR: (CDCl3, 400 MHz) [The compound exists as a mixture of keto-enol 
tautomers]  3.78 (2H, s, -CH2), 3.89-3.98 (12H, 4 x -OCH3), 5.98 (1 H, s, H-5), 5.99 (1 H, s, 
H-3), 6.02 (1H, s, =CH of enol form), 6.93 (1H, d, J= 8.5 Hz, H-6’), 7.27 (1H, d, J= 7.0 Hz, H-
5’), 7.44 (1H, s, H-2’), 13.44 (1H, s, OH), 13.72 (1H, s, OH of enol form). 
4.1.2.3 2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4H-chomen-4-one (9) 
1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-phenyl propane-1, 3-dione (8) (0.75g, 2.08 mmol) was 
dissolved in acetic acid (6 mL) and  heated to 90 
o
C for 1 h. Concentrated sulfuric acid (0.06 
mL, 1% v/v of acetic acid) was added and the reaction was heated at 110 
o
C for 1 h. The 
reaction mixture was cooled to room temperature, diluted with water (10 mL) and the aqueous 
layer was extracted with EtOAc (2 x 5 mL). The organic layers were combined, dried over 
anhydrous magnesium sulfate and concentrated in vacuo to obtain the crude 2-(3,4-
dimethoxyphenyl)-5,7-dimethoxy-4H-chomen-4-one. The pure compound was obtained as a 
white solid after purification by column chromatography [Hexane: CHCl3: EtOAc (3:6:1 v/v/v)]. 
Yield: 70%; m.p: 192-93 
o
C (lit [37]-190-94 
o
C); 
1
H NMR: (DMSO-d6, 400 MHz)  3.82 (3H, 
s, -OCH3) 3.83 (3H, s, -OCH3), 3.87 (3H, s, -OCH3), 3.89 (3H, s, -OCH3), 6.49 (1H, s, H-3), 
6.76 (1H, s, H-6), 6.86 (1H, s, H-8), 7.01 (1H, d, J= 8.5 Hz, H-6’), 7.52 (1H, s, H-2’), 7.63 (1H, 
d, J= 8.0 Hz, H-5’); 13C NMR: (DMSO-d6, 100 MHz)  55.9 (-OCH3), 93.4 (C8), 96.3 (C6), 
107.0 (C3’), 107.9 (C10), 108.7 (C6’), 111.5 (C3’), 119.2 (C2’), 122.9 (C1’), 149.1 (C4’), 151.5 
(C5’), 159.0 (C9), 159.3 (C5), 160.4 (C2), 163.9 (C7), 175.7 (C=O); IR νmax [cm
-1
]: 1644 
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(C=O, ν, m), 1252 (-OCH3, ν, m) 1138 (C-O, ν, m); m/z (FTMS+ESI):M+H (C19H19O6) 
requires 343.1176, found 343.1176. HPLC purity: 99.5% 
4.1.2.4 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chomen-4-one (10) 
2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4H-chomen-4-one (9) (100 mg, 0.292 mmol) was 
dissolved in anhydrous DCM (1 mL). BBr3 (329.32 mg, 0.126 mL, 1.314 mmol, 4.5 eq., d=2.60 
g/mL) was added and stirred at 40 
o
C overnight. The reaction was cooled to room temperature 
and diluted with water (2 mL). The pH was adjusted to 6 with 5% Na2HPO4 and the aqueous 
layer was extracted with n-butanol (2 x 5 mL). The organic layer was washed with brine, dried 
over anhydrous magnesium sulfate and concentrated in vacuo. The crude product was purified 
by column chromatography [Solvent system: EtOAc (100 %)] to afford 2-(3, 4-
dihydroxyphenyl)-5,7-dihydroxy-4H-chomen-4-one (10) as a pale yellow solid. 
Yield: 59%; m.p:328-29 
o
C (lit [38]-326-28 
o
C); 
1
H NMR: (DMSO-d6, 400 MHz)  6.25 (1H, 
s, H-3), 6.50 (1H, s, H-6), 6.72 (1H, s, H-8), 6.95 (1H, d, J= 8.0 Hz, H-6’), 7.45 (1H, s, H-2’), 
7.46 (1H, d, J= 8.0 Hz, H-5’), 9.48 (1H, s, OH), 9.98 (1H, s, OH), 10.90 (1H, s, OH), 13.02 (1H, 
s, OH) ; 
13
C NMR: (DMSO-d6, 100 MHz)  93.7 (C8), 98.8 (C6), 102.6 (C3), 103.6 (C10), 
113.2 (C2’), 115.9 (C5’), 118.9 (C6’), 121.4 (C1’), 145.6 (C3’), 149.6 (C4’), 157.2 (C9), 161.4 
(C5), 163.8 (C2), (164.0, C7), 181.6 (C=O); IR νmax [cm
-1
]: 1600 (C=O, ν, s), 1160 (C-O, ν, m), 
3236 (OH, w, b); IR νmax [cm
-1
]: 1600 (C=O, ν, s), 1160 (C-O, ν, m), 3236 (OH, w, b); m/z 
(FTMS+ESI): M+H (C15H11O4) requires 287.0550, found 287.0554. HPLC purity: 99.4% 
4.1.2.5 Synthesis of 2-(3,4-dimethoxyphenyl)-5,7-dimethoxy-4H-chromene-4-thione (11) 
2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4H-chomen-4-one (9) (0.25 g, 0.73 mmol) was 
dissolved in anhydrous toluene (1 mL), Lawesson’s reagent (0.30 g, 0.73 mmol, 1 eq.) was 
added and the reaction was heated to 110 
o
C for 4 h. The reaction mixture was cooled to room 
temperature and concentrated in vacuo. The residue was purified by column chromatography 
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[Solvent system: Hexane: CHCl3: EtOAc (3:6:1 v/v/v)] to obtain the pure compound as a green 
solid.  
Yield: 61%; m.p: 204-5 
o
C (lit [36]-203 
o
C); 
1
H NMR: (DMSO-d6, 400 MHz)  3.82 (3H, s, -
OCH3) 3.86 (3H, s, -OCH3), 3.90 (3H, s, -OCH3), 3.94 (3H, s, -OCH3), 6.58 (1H, s, H-2’), 6.94 
(1H, s, H-8), 7.13 (1H, d, J= 8.0 Hz, H-5’), 7.53 (1H, s, H-3), 7.55 (1H, s, H-6), 7.69 (1H, d, J= 
8.0 Hz, H-6’);  13C NMR: (DMSO-d6, 100 MHz)  53.6 (-OCH3), 53.7 (-OCH3), 53.8 (-OCH3), 
54.0 (-OCH3), 91.2 (C8), 94.8 (C6), 107.0 (C2’), 109.8 (C5’), 114.3 (C10), 117.8 (C3), 118.1 
(C6’), 120.2 (C1’), 147.0 (C4’), 147.2 (C3’), 149.7 (C2), 152.9 (C9), 158.7 (C7), 161.4 (C5), 
196.7 (C=S); IR νmax[cm
-1
]: 1316 (C=S, ν, m), 1254 (-OCH3, ν, m) 1140 (C-O, ν, m); m/z 
(FTMS+ESI):  M+H (C19H19O5S) requires 359.0948, found 359.0948. HPLC purity: 95.7% 
4.1.2.6 Synthesis of 2-(3, 4-dihydroxyphenyl)-5, 7-dihydroxy-4H-chromene-4-thione (12) 
2-(3,4-Dimethoxyphenyl)-5,7-dimethoxy-4H-chromene-4-thione (11) (0.15 g, 0.418 mmol) was 
dissolved in anhydrous DCM (1 mL). BBr3 (0.47 g, 0.181 mL, 1.86 mmol, 4.45 eq., d=2.60 
g/mL) was added and the reaction was stirred at 40 
o
C overnight. The reaction was cooled to 
room temperature and diluted with water (2 mL). The pH was adjusted to 6 with 5% Na2HPO4 
and the precipitated product was filtered and purified by column chromatography [Solvent 
system: EtOAc (100 %)] to obtain the pure compound as a brown solid. 
Yield: 55%; m.p: 269-70 
o
C; 
1
H NMR: (DMSO-d6, 400 MHz)  6.29 (1H, s, H-2’), 6.51 (1H, 
s, H-8), 6.89 (1H, d, J= 8.0 Hz, H-5’), 7.31 (1H, s, H-3), 7.43 (1H, s, H-6), 7.49 (1H, d, J= 8.0 
Hz, H-6’), 9.80 (1H, s, OH), 10.12 (1H, s, OH), 11.20 (1H, s, OH), 13.67 (1H, s, OH);  13C 
NMR: (DMSO-d6, 100 MHz)  94.4 (C8), 100.5 (C6), 111.6 (C10), 113.5 (C2’), 115.7 (C5’), 
116.2 (C3), 119.7 (C1’), 120.1 (C6’), 145.9 (C3’), 150.3 (C4’), 153.9 (C2), 155.1 (C9), 161.7 
(C7), 164.0 (C5), 194.5 (C=S); IR νmax [cm
-1
]: 1444 (C=S, ν, m), 1146 (C-O, ν, m), 3293 (OH, 
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w, b); m/z (FTMS+ESI): M+H (C15H11O5S) requires 303.0322, found 303.0326. HPLC purity: 
99.3% 
 
4.1.3 In vitro cell migration (Scratch assay) 
HUVECs were seeded in 12-well plates at 3 x 104 cells/well and cultured for 48 h. After 48 h, 
they were serum-starved (0.1% serum) for 24 h to inactivate the cell proliferation. A scratch was 
performed on the cell monolayers using a 100 μL pipette tip. Cells were then washed twice with 
PBS and then treated with medium containing VEGF (10 ng/mL) and either quercetin, luteolin, 
or one of the synthesised derivatives (at 10 μM or 1 μM). Images of the scratches were taken 
immediately after performing the scratch (t = 0 h) and at 12 h (t = 12 h). The area not covered by 
the cells was quantified using ImageJ software. Data were normalized to the presence or absence 
of VEGF (VEGF and VEGF-free medium were set at 100% and 0%, respectively). 
4.1.4 Cell viability (MTT assay) 
MCF-7 and MCF-7/DX cells were seeded at a density of 4 x 104 into 96 well plates and 
incubated to allow the attachment for 24 h. After 24 h, the cells were treated with either 
quercetin, luteolin or one of the synthesised derivatives at range of concentrations (0 to 250 µM) 
for 67 h. After 67 h, 20 µL of MTT (5mg/mL) solution in PBS was added to each well and the 
cells were incubated for 5 h. The purple crystals formed were dissolved in 100 µL of DMSO and 
the plates were read at 570 nm using a SPECTRA max UV spectrometer (Bio-Rad).The data 
represented are the mean of the three individual experiments. 
4.1.5 Western blotting 
HUVECs were cultured in 6-well plates at 1 x 105 cells/well and cultured for 48 h. After 48 h, 
they were serum-starved (0.1% serum) for 24 h to inhibit cell proliferation. Cells were then 
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pretreated with or without quercetin, luteolin or one of their derivatives for 1 h, followed by 
stimulation with 10 ng/mL of VEGF for 15 min (for VEGFR2 activation). Cells were washed 
twice with ice-cold PBS and lysed using 100 μL radioimmunoprecipitation assay (RIPA) lysis 
buffer with 1% protease inhibitor and phosphatase inhibitor.  The amount of protein present 
in the cell lysate was assessed using the DC (Bio-Rad) protein assay developed from Lowry’s 
protocol for protein assessment. Proteins (15 µg) were separated by SDS-PAGE and then 
transferred to PVDF membranes. Membranes were blocked with 3% fat-free dry milk in PBT 
buffer and then probed for PTyr-1175-VEGFR2 (1:1000) or total VEGFR2 (1:1000) and actin 
dilution. Protein bands were detected by incubating with horseradish peroxidase-conjugated 
antibodies (1:10,000) and visualised with enhanced chemiluminescence reagent using 
ImageQuant LAS 4000 (GE Healthcare). Gelbands were standardised to total protein loading 
relative to actin by using a Gel-Pro analyzer6.0 software as previously described [39]. 
4.1.6 Molecular docking 
Docking validation-To validate the accuracy of the docking procedure to be used, the original 
ligands were extracted from the coordinate files (taken from the Protein Data Bank PDB), and 
then docked again into the corresponding crystal structure of the proteins, using the automated 
docking procedure in the program Surflex-Dock (SFXC) [40], as provided by SYBYL-X2.1. 
The resulting ligand conformation from the docking procedure was compared with the ligand 
conformation as found in the actual crystal structure of the complex. Comparative structural 
orientation of the ligand was calculated as the root mean square deviation (RSMD) between the 
docked ligand and the ligand as found in the crystal structure, using the programme LSQKAB, 
as provided in the CCP4 [41] suite. If the root mean square deviation (RMSD) value between 
the real and the best-scored conformations is equal to or less than 2.0 Å (representing the grid 
spacing used for the docking procedure), then the docking process was considered successful 
[42].  
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Docking procedure- Docking studies were performed using the program Surflex-Dock (SFXC) 
as provided by Sybyl-X 2.1. The X-ray crystallographic structures of human VEGFR2 receptor 
complexed with 4-amino-furo[2,3-d]pyrimidine (PDB code1YWN, 1.71 Å resolution) [43] and 
human VEGF protein complexed with receptor blocking peptide (PDB code1VPP, 1.90 Å 
resolution) [44] were retrieved from the Protein Data Bank. The protein structures were prepared 
for docking using the Biopolymer Structure Preparation Tool with the implemented default 
settings provided in the SYBYL programme suite. Hydrogens were added to the protein 
structures in idealised geometries and an overall energy minimisation of each protein was 
performed using the MMFF94 force field, employing a conjugate gradient algorithm [45] with a 
convergence criterion of 0.5 kcal/mol A−1and up to 5000 iterations. Finally, before the docking 
run, all water molecules were removed and the ligand 4-amino-furo[2,3-d]pyrimidine was 
extracted from the coordinate file of the VEGFR2 receptor (1YWN). The protomol, representing 
the ligand binding groove, was generated using a ligand directed method for VEGFR2, which 
allows the docking of ligands into predefined sites, as defined by occupancy of any co-
crystallised ligand at the site of interest. In the case of VEGF, as the crystal structure was not 
bound to any ligand, the protomol was generated using the automatic docking procedure.  
The Surflex-X docking algorithm docks a given ligand to a receptor using a flexible ligand and a 
semi-flexible receptor; in this case the peptides were allowed to be fully flexible while the 
receptor was semi-flexible. This allows for optimisation of potentially favourable molecular 
interactions, such as those defined by hydrogen bond and van der Waal forces. The docking 
results yield a docking score, which takes into consideration entropic, polar, hydrophobic, 
repulsive and desolvation factors. The docking scores were expressed in –log10 (Kd) units to 
represent binding affinities, where Kd is the dissociation constant. The free energy of binding of 
the ligand to the protein was extrapolated from equation (1). 
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Free energy of binding = RTlogeKd  (1) 
The docking results were visualised using the program PyMOL [46,47] and the molecular 
interactions of the docked ligands were analysed by the programme CONTACTS, as provided in 
the CCP4 suite of programs [41],[48],[49]. Potential hydrogen bonds were assigned if the 
distance between two electronegative atoms was less than 3.3 Å, whereas any separation greater 
than 3.3 Å, but less than 4.5 Å, was considered a van der Waal interaction. 
4.1.7 DSC (Membrane perturbation effect) 
DSC measurements were performed using the differential scanning calorimeter nano-DSC (TA 
instruments, UK). The samples were degassed before being loaded into the reference and sample 
cells. A scan rate of 1.5 °C/min over the temperature range 20-70 °C was employed. Data were 
analysed using nano analyser software provided by TA instrument. 
Liposome preparation: Model membranes [multilamellar vesicles (MLVs)] were prepared using 
dipalmitoylphosphatidylcholine (DPPC) lipid. DPPC was dissolved in chloroform and the 
solvent was evaporated under vacuum to obtain a lipid film. The resulted lipid film was 
hydrated with an appropriate volume of 20 mM sodium phosphate buffer at pH 7.0 at room 
temperature, followed by 3-4 freeze-thawing cycles. For DSC experiments, samples were 
prepared by mixing the lipid and drug solutions to obtain 0.2 mg/mL of lipid and 10 or 100 μM 
of compound-1 to 3 and 9 to 11.   
ASSOCIATED CONTENT 
Supporting Information. 1H NMR spectra of compounds 2-4 and 9-12 and DSC profiles of 
compounds 1-3 and 9-12 are provided here.  This material is available online. 
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List of captions of schemes, figures and tables.  
Scheme 1- Synthesis of methoxy and 4-thiocarbonyl analogues of quercetin 
Scheme 2- Synthesis of luteolin and its methoxy and 4-thiocarbonyl analogues 
Figure 10. The quercetin and luteolin derivatives synthesised and evaluated in this study.  
Figure 11. Effects of quercetin and its derivatives on VEGF-mediated cell migration in an in vitro scratch assay. 
A- Representative images of scratch assay of HUVEC with the treatments, -ve control- without VEGF, +ve 
control- with VEGF (10 ng/mL), quercetin (1) [10 µM + 10 ng/mL VEGF], quercetin (1) [1 µM + 10 ng/mL 
VEGF], thioquercetin (4)  [1 µM + 10 ng/mL VEGF], methoxyquercetin (2) [10 µM + 10 ng/mL VEGF], 
thiomethoxyquercetin (3)  [10 µM + 10 ng/mL VEGF]. The images were acquired at 10X maginification, size 
bar 50 µM. Dashed lines represent the margins of the initial scratch, area covered by HUVEC after 12 h was 
quatified using ImageJ software. B- Bar chart represent the quantification of the inhibitory effect of quercetin 
and its derivatives on VEGF stimulated  migration, expressed as percentage of the scratched area covered by 
HUVEC after 12 h migration and normalized to presence/absence of VEGF (100% and 0% for VEGF and 
VEGF-free medium, respectively). The results for compound-4 at 10 µM is not reported as signs of toxicity 
were observed for that compound at 10 µM concentration.  Data are expressed as mean± standard error of the 
mean (SEM), n = 3. Statistical significance was estimated with respect to the +ve control by one-way ANOVA, 
followed by Bonferroni’s post hoc test (ns = nonsignificant; *, p < 0.05, **, p < 0.01, ***, p < 0.001,****,  p < 
0.0001). 
Figure 12. Effects of luteolin and its derivatives on VEGF-mediated cell migration in an in vitro scratch assay. 
A- Representative images of scratch assay of HUVEC with the treatments, -ve control- without VEGF, +ve 
control- with VEGF (10 ng/mL), luteolin (10) [1 µM + 10 ng/mL VEGF], thioluteolin (12) [1 µM + 10 ng/mL 
VEGF], methoxyluteolin (9) [10 µM + 10 ng/mL VEGF], thiomethoxyluteolin (11) [10 µM + 10 ng/mL VEGF]. 
The images were acquired at 10X magnification, size bar 50 µM. Dashed lines represent the margins of the 
initial scratch, area covered by HUVEC after 12 h was quatified using ImageJ software. B-Bar chart represent 
the quantification of the inhibitory effect of luteolin and its derivatives on VEGF stimulated migration, 
expressed as percentage of the scratched area covered by HUVEC after 12 h migration and normalized to 
presence/absence of VEGF (100% and 0% for VEGF and VEGF-free medium, respectively). The results for 
compounds-10 and 12 at 10 µM are not reported as signs of toxicity were observed for those compounds at 10 
µM concentration. Data are expressed as the mean ± standard error of the mean (SEM), n = 3. Statistical 
significance was estimated with respect to the +ve control by one-way ANOVA, followed by Bonferroni’s post 
hoc test (ns = nonsignificant; *, p < 0.05, ***, p < 0.001, ****, p < 0.0001).  
 
Figure 13. A-Representative Western blot images of HUVEC proteins with the treatments, -ve control- without 
VEGF, +ve control- with VEGF (10 ng/mL), quercetin (1) [10 µM + 10 ng/mL VEGF], quercetin (1) [1 µM + 
10 ng/mL VEGF], thioquercetin (4)  [1 µM + 10 ng/mL VEGF], methoxyquercetin (2)  [10 µM + 10 ng/mL 
VEGF], thiomethoxyquercetin (3)  [10 µM + 10 ng/mL VEGF], luteolin (10) [1 µM + 10 ng/mL VEGF], 
methoxyluteolin (9) [10 µM + 10 ng/mL VEGF], thiomethoxyluteolin (11)  [10 µM + 10 ng/mL VEGF]; actin 
was used as a loading control. B- Bar chart represents the quantification of the inhibitory effect of quercetin, 
luteolin and its derivatives on VEGF induced phosphorylation. Data are expressed as mean ± standard error of 
the mean (SEM), n = 3. Statistical significance was estimated vs the +ve control by one-way ANOVA, followed 
by Bonferroni’s post hoc test (#-significant with respect to –ve control, ns = nonsignificant; *, p < 0.05, ***, p < 
0.001, ****, p < 0.0001).  
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Figure 14. Docking modes of quercetin (1) (A), methoxy quercetin (2) (B), thiomethoxy quercetin (3) (C), 
thioquercetin (4) (D), luteolin (10) (E), methoxy luteolin (9) (F), thiomethoxy luteolin (11) (G), thioluteolin (12) 
(H) with VEGFR2. 
Figure 15. Docking modes of quercetin (1) (A), methoxy quercetin (2) (B), thiomethoxy quercetin (3) (C), 
thioquercetin (4) (D), luteolin (10) (E), methoxy luteolin (9) (F), thiomethoxy luteolin (11) (G), thioluteolin (12) 
(H) with VEGF. 
Figure 16. Representative DSC profiles of  DPPC MLV’s illustrating the effect in the presence of (A) Genistein 
at 10 µM (G-10 µM), 60 µM (G-60 µM), and 100 µM (G-100 µM) in comparison with DPPC alone; (B) 
Quercetin and its derivatives (at 10 times the concentration at which antiangiogenic effects were observed): 
compound-1 at 100 µM, compound-2 at 100 µM, compound-3 at 100 µM in comparison with genistein at 100 
µM and DPPC alone; (C) Luteolin and its derivatives (at 10 times the concentration at which antiangiogenic 
effects were observed): compound-9 at 100 µM, compound-10 at 10 µM, compound-11 at 100 µM in 
comparison with genistein at 100 µM and DPPC alone. 
Figure 17.  Dose-dependent cytotoxicity curves of quercetin (1), thioquercetin (4), methoxy quercetin (2) and 
thiomethoxy quercetin (3) (A) against MCF-7 (B) against MCF-7/DX. Dose-dependent cytotoxicity curves of 
luteolin (10), thioluteolin (12) methoxyluteolin (9) and  thiomethoxyluteolin (11) (C) against MCF-7 (D) against 
MCF-7/DX. Data are expressed as the mean ± standard error of the mean (SEM), n = 3. 
Figure 18. General SAR of quercetin and luteolin derivatives 
Table 1. Thermodynamic parameters obtained by DSC for the interaction of DPPC 
with compounds 1-3 and 9-11
a 
Table 2. IC50 values of quercetin, luteolin and their derivatives
a
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